CIK 0001531177
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Sight Sciences, Inc.
Sign in to watch- Ticker
- SGHT
- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 800625749
- Phone
- +1 415-889-0550
- Business address
- 4040 CAMPBELL AVE,, SUITE 100, MENLO PARK, CA, 94025
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $652,777
- in 5 filings, $653K under 10b5-1 plans
Net −$652,777. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Badawi Paul −$268K President and CEO sold <1% of stake
- Bauerlein Alison −$224K Chief Operating Officer sold 4% of stake
- Badawi David −$71K Chief Technology Officer sold <1% of stake
- Rodberg James −$64K Chief Financial Officer sold 3% of stake
- Taylor Brenton −$26K EVP, Operations & R&D sold 1% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-11-22 | Encrantz Staffan Director | Purchase | +41,085 | $2.50 | $103K | 346,295 |
| 2023-11-21 | Encrantz Staffan Director | Purchase | +68,477 | $2.48 | $170K | 305,210 |
| 2023-11-20 | Encrantz Staffan Director | Purchase | +79,234 | $2.25 | $178K | 236,733 |
| 2023-11-17 | Encrantz Staffan Director | Purchase | +126,664 | $2.19 | $277K | 157,499 |
| 2023-11-16 | Encrantz Staffan Director | Purchase | +339 | $2.00 | $678 | 30,835 |
| 2023-11-14 | Link Matthew Chief Commercial Officer | Grant or award | +747,572 | 747,572 | ||
| 2023-11-14 | Link Matthew Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +526,430 | 526,430 | ||
| 2023-11-14 | Encrantz Staffan Director | Purchase | +3,462 | $2.00 | $7K | 30,496 |
| 2023-09-14 | Park Sam Boong Chief Operating Officer | Option exercise | +31,668 | $1.96 | $62K | 83,092 |
| 2023-09-14 | Park Sam Boong Chief Operating Officer | Option exercise | +6,000 | $1.96 | $12K | 89,092 |
| 2023-09-14 | Park Sam Boong Chief Operating Officer | Option exercise · Stock Option (Right to Buy) | −31,668 | 10,000 | ||
| 2023-09-14 | Park Sam Boong Chief Operating Officer | Option exercise · Stock Option (Right to Buy) | −6,000 | 3,668 | ||
| 2023-06-08 | Encrantz Staffan Director | Grant or award | +11,940 | 11,940 | ||
| 2023-06-08 | Encrantz Staffan Director | Grant or award | +15,094 | 27,034 | ||
| 2023-06-08 | Mazzacco Catherine Director | Grant or award | +30,189 | 0 | ||
| 2023-06-08 | Schroeder Valeska Director | Grant or award | +11,940 | 11,940 | ||
| 2023-06-08 | Rogers Erica J. Director | Grant or award | +11,940 | 87,356 | ||
| 2023-06-08 | Rogers Erica J. Director | Grant or award | +15,094 | 87,356 | ||
| 2023-06-08 | Zurbay Donald Director | Grant or award | +11,940 | 74,440 | ||
| 2023-06-08 | Zurbay Donald Director | Grant or award | +15,094 | 74,440 |
Page 10 of 16 · 302 trades